Edwards Lifesciences Corporation $EW Stock: Assenagon Asset Management S.A. Boosts Stake

Key Points

• Assenagon Asset Management increased its Edwards Lifesciences stake by 50% in the third quarter, adding 906,345 shares to own 2.72 million shares worth approximately $234.7 million. Institutional investors collectively own 79.46% of the company.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $100.27; recent targets range from $95 to $110.
• Edwards Lifesciences exceeded quarterly expectations, reporting adjusted EPS of $0.78 versus the $0.74 estimate and revenue of $1.74 billion, up 13.6% year over year. Insiders, however, sold 5,045 shares worth $451,596 over the prior three months.

Assenagon Asset Management S.A. grew its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 50.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,719,271 shares of the medical research company's stock after buying an additional 906,345 shares during the quarter. Assenagon Asset Management S.A. owned 0.47% of Edwards Lifesciences worth $234,727,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in EW. BlackRock Inc. bought a new position in Edwards Lifesciences during the second quarter valued at $5,318,092,000. Varma Mutual Pension Insurance Co purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at $11,168,000. Conway Capital Management Inc. purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at $954,000. Commerce Bank bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth about $3,121,000. Finally, Bank of America Corp DE bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth about $605,397,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. TD Cowen reaffirmed a "buy" rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Piper Sandler reiterated an "overweight" rating and set a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. BTIG Research reissued a "buy" rating and issued a $110.00 price objective on shares of Edwards Lifesciences in a research report on Friday, September 11th. Weiss Ratings reissued a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Finally, Truist Financial increased their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "hold" rating in a report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $100.27.

Insiders Place Their Bets

In other news, VP Daniel Lippis sold 619 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares of the company's stock, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of the firm's stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the transaction, the senior vice president directly owned 14,868 shares in the company, valued at approximately $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 5,045 shares of company stock worth $451,596 in the last three months. Corporate insiders own 0.31% of the company's stock.

Edwards Lifesciences Stock Up 1.8%

Shares of EW opened at $88.05 on Friday. The firm has a fifty day moving average price of $88.51 and a 200-day moving average price of $86.33. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $50.70 billion, a P/E ratio of 30.76, a P/E/G ratio of 2.27 and a beta of 0.87. Edwards Lifesciences Corporation has a 12-month low of $72.42 and a 12-month high of $96.29.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter last year, the firm posted $0.67 EPS. The firm's revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts expect that Edwards Lifesciences Corporation will post 3.00 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.